Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, No. 18, Chaowang Road, Gangshu District, Hangzhou, Zhejiang, 310014, China.
Zhejiang Provincial Key Laboratory of TCM for Innovative R & D and Digital Intelligent Manufacturing of TCM Great Health Products, No. 999 Changhong East Street, Huzhou City, Zhejiang, 310023, China.
Comb Chem High Throughput Screen. 2024;27(3):479-496. doi: 10.2174/0113862073261351231005111817.
This study investigated the molecular action mechanism of a compound herb, also known as the throat-clearing formula (QYF), by using network pharmacology and animal experimental validation methods to treat chronic pharyngitis (CP).
The active ingredients and disease targets of QYF were determined by searching the Batman-TCM and GeneCards databases. Subsequently, the drug-active ingredient-target and protein-protein interaction networks were constructed, and the core targets were obtained through network topology. The Metascape database was screened, and the core targets were enriched with Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes.
In total, 1403 and 241 potential targets for drugs and diseases, respectively, and 81 intersecting targets were yielded. The core targets included TNF, IL-6, and IL-1β, and the core pathways included PI3K-Akt. The QYF treatment group exhibited effectively improved general signs, enhanced anti-inflammatory ability , reduced serum and tissue expressions of TNF- α, IL-6, and IL-1β inflammatory factors, and decreased blood LPS levels and Myd88, TLR4, PI3K, Akt, and NF-κB p65 protein expression in the tissues.
QYF could inhibit LPS production, which regulated the expression of the TLR4/PI3K/Akt/NF-κB signaling pathway to suppress the expression of the related inflammatory factors (i.e., TNF-α, IL-6, and IL-1β), thereby alleviating the CP process.
本研究采用网络药理学和动物实验验证方法,探讨一种复方草药(也称为利咽方,QYF)治疗慢性咽炎(CP)的分子作用机制。
通过搜索 Batman-TCM 和 GeneCards 数据库,确定 QYF 的活性成分和疾病靶点。然后,构建药物-活性成分-靶标和蛋白质-蛋白质相互作用网络,并通过网络拓扑获取核心靶标。使用 Metascape 数据库对核心靶标进行筛选,并对基因本体论和京都基因与基因组百科全书进行富集分析。
共得到 1403 个药物潜在靶点和 241 个疾病潜在靶点,有 81 个交集靶点。核心靶点包括 TNF、IL-6 和 IL-1β,核心通路包括 PI3K-Akt。QYF 治疗组的一般体征得到了有效改善,抗炎能力增强,血清和组织中 TNF-α、IL-6 和 IL-1β 炎症因子的表达降低,组织中 LPS 水平和 Myd88、TLR4、PI3K、Akt 和 NF-κB p65 蛋白表达降低。
QYF 可以抑制 LPS 的产生,调节 TLR4/PI3K/Akt/NF-κB 信号通路的表达,抑制相关炎症因子(TNF-α、IL-6 和 IL-1β)的表达,从而缓解 CP 进程。